<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578239</url>
  </required_header>
  <id_info>
    <org_study_id>AAA-III-01</org_study_id>
    <secondary_id>2011-005049-11</secondary_id>
    <nct_id>NCT01578239</nct_id>
  </id_info>
  <brief_title>A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours</brief_title>
  <acronym>NETTER-1</acronym>
  <official_title>A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Accelerator Applications</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Accelerator Applications</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to

        -  compare Progression Free Survival (PFS) after treatment with 177Lu-DOTA0-Tyr3-Octreotate
           plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg)
           Octreotide LAR in patients with inoperable, progressive (as determined by Response
           Evaluation Criteria in Solid Tumors [RECIST] Criteria), somatostatin receptor positive,
           well-differentiated neuroendocrine tumours of the small bowel (midgut carcinoid
           tumours).

        -  compare the Objective Response Rate (ORR) between the two study arms

        -  compare the Overall Survival (OS) between the two study arms

        -  compare the Time to Tumour Progression (TTP) between the two study arms

        -  evaluate the safety and tolerability of 177Lu-DOTA0-Tyr3-Octreotate

        -  evaluate the health related quality of life (QoL) as measured by the European
           Organization for Research and Treatment of Cancer (EORTC) QLQ-G.I.NET21 questionnaire

        -  explore the correlation of toxicity outcomes and administered radiation doses corrected
           for body weight and body surface area

        -  explore the correlation of clinical efficacy outcomes with the levels of the biomarkers
           Chromogranin-A (CgA) in the serum and 5-Hydroxyindoleacetic acid (5-HIAA) in the urine

        -  evaluate dosimetry, pharmacokinetics (PK) and ECG in a subset of 20 patients

        -  explore the correlation of clinical efficacy outcomes with OctreoScan® tumour uptake
           score

        -  explore the correlation of clinical outcomes with serum levels of Alkaline Phosphatase
           (AP)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III
      study. In this study, treatment with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care
      (30 mg Octreotide LAR) will be compared to treatment with high dose (60 mg) Octreotide LAR in
      patients with inoperable, somatostatin receptor positive, histologically proven midgut
      carcinoid tumours; these patients should be progressive under Octreotide LAR. In case
      patients in either arm experience clinical symptoms (i.e. diarrhoea and flushing) associated
      with their carcinoid tumours, Octreotide s.c. rescue injections are allowed.

      Objective tumour response in both arms will be assessed every 12±1 weeks from the first
      treatment date according to RECIST Criteria. The baseline CT scan/MRI must not be older than
      4 weeks before the projected randomization date.

      Patients will be evaluated for safety and tolerability in accordance with the Visit Schedules
      for the 177Lu-DOTA0-Tyr3-Octreotate arm and the Octreotide LAR arm as indicated in Table 1
      and Table 2, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>after 74 centrally confirmed cases disease progression or death</time_frame>
    <description>Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
CT/MRI tumour assessment in both arms are performed every 12±1 weeks from the first treatment date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments (Adverse Events, Laboratory Parameters, Cancer Related Symptoms, Physical Examination, Vital Signs, Karnofsky Performance Status, ECG)</measure>
    <time_frame>Data for this outcome measure are posted in the Adverse Events section below. Adverse Events table includes all treatment emergent adverse events collected from date of first enrollment (10 Jul 2012) to 30 June 2016.</time_frame>
    <description>The following parameters will be monitored:
Changes from Baseline in Hematology (WBC, platelets, haemoglobin, MCV), Blood chemistry (BUN, serum creatinine and creatinine clearance, uric acid, albumin, total bilirubin, AP, aspartate aminotransferase [AST/ASAT], alanine aminotransferase [ALT/ALAT], gamma-glutamyl transferase [γ-GT], [Na], [K], lactic dehydrogenase [LDH], glycosylated hemoglobin/hemoglobin A1c [glycoHb], free thyroxine [fT4]) and Urinalysis (RBC/hpf, WBC/hpf, casts/lpf, protein, 5-HIAA),
Cancer related symptoms,
Physical Examination, including heart rate, blood pressure and weight,
Karnofsky Performance Status,
ECG intervals.
All AEs and SAEs reported (spontaneously or not) by the patient will be collected during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Safety and Efficacy Assessment</measure>
    <time_frame>Every 6 months for a period of up to 5 years after the end of the study</time_frame>
    <description>Any progressive patient ceases treatment/assessment and proceeds to long-term follow-up assessment.
Any non-progressive patients continues treatment/assessments until the PFS Primary End-Point, then:
Patients who have 76week or more treatment/assessment stop treatment but continue the long-term follow-up assessments for 5 years overall from the date of randomization of the last randomized.
Remaining randomized patients continue in the fixed 76-week treatment/assessment phase unless progression occurs, then proceed to the long-term follow-up assessment phase for 5 years overall from the date of randomization of the last randomized patient.
During the long-term follow-up assessment phase, toxicities suspected in relation with the study drug (including haematology, biochemistry, urine analyses), anti-tumour treatment administered after progression/discontinuation, disease status based on local CT/MRI assessment, and OS data will be collected every 6 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Objectives</measure>
    <time_frame>Study Treatment Phase</time_frame>
    <description>To explore the correlation of toxicity outcomes and administered radioactivity corrected for body weight and body surface area;
To explore the correlation of clinical efficacy outcomes with the levels of the biomarkers Chromogranin-A (CgA) in the serum and 5-Hydroxyindoleacetic acid (5-HIAA) in the urine;
To evaluate dosimetry, pharmacokinetics (PK) and ECG in a subset of 20 patients;
To explore the correlation of clinical efficacy outcomes with OctreoScan® tumour uptake score;
To explore the correlation of clinical outcomes with serum levels of Alkaline Phosphatase (AP):
To evaluate the Duration of Response (DoR) in the two study arms;
To evaluate the Time to Second Progression (PFS2) in the two study arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Carcinoid Tumor of the Small Bowel</condition>
  <condition>Neuroendocrine Tumour</condition>
  <arm_group>
    <arm_group_label>177Lu-DOTA0-Tyr3-Octreotate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg Octreotide LAR treatment for symptom control will continue until the end of study, unless the patient progresses or dies;
Treatment will consist of a cumulative dose of 29.6 gigaBecquerel (GBq) (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate;
Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate;
Concomitant amino acids will be given with each administration for kidney protection;
177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity (see Dose Modifying Toxicity (DMT) below); in case patients experience clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections are allowed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octreotide LAR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the patient progresses or dies (see Dose Modifying Toxicity (DMT));
In case patients experience clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections are allowed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide LAR</intervention_name>
    <description>In the experimental arm, 30 mg Octreotide LAR treatment will be given to the patients until the end of study for symptom control purpose, unless the patient progresses or dies.
In the active comparator arm, 60 mg Octreotide LAR treatment will be given to the patients every 4 weeks (i.m. injections) until the end of the study, unless the patient progresses or dies.</description>
    <arm_group_label>177Lu-DOTA0-Tyr3-Octreotate</arm_group_label>
    <arm_group_label>Octreotide LAR</arm_group_label>
    <other_name>SANDOSTATIN LAR, Octreotide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-DOTA0-Tyr3-Octreotate</intervention_name>
    <description>Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity;</description>
    <arm_group_label>177Lu-DOTA0-Tyr3-Octreotate</arm_group_label>
    <other_name>Lutathera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Presence of metastasized or locally advanced, inoperable (curative intent) at
             enrollment time, histologically proven, midgut carcinoid tumour (to be centrally
             confirmed).

          2. Ki67 index ≤ 20% (to be centrally confirmed).

          3. Patients on Octreotide LAR at a fixed dose of 20 mg or 30 mg at 3-4 weeks intervals
             for at least 12 weeks prior to randomization in the study.

          4. Patients ≥18 years of age.

          5. Patients must have progressive disease based on RECIST Criteria, Version 1.1 while
             receiving an uninterrupted fixed dose of Octreotide LAR (20-30 mg/3-4 weeks). Disease
             progression must be centrally confirmed. In order to make the assessment, two CT (or
             MRI) scans are required. The oldest scan must not be older than 3 years from the date
             of randomization. The most recent scan must not be older than 4 weeks from the date of
             randomization. Both scans must be obtained while the patient is receiving the same
             fixed dose of Octreotide LAR (20-30 mg/3-4 weeks) with the following exceptions; 1) it
             is acceptable if the oldest scan is obtained within 12 weeks of the patient receiving
             a fixed dose regimen of Octreotide LAR (20-30 mg/3-4 weeks); AND 2) it is acceptable
             for either scan to be obtained before or during the time a patient receiving a fixed
             dose of Octreotide LAR has switched to an equivalent dose of short acting Octreotide
             for up to 6 weeks in order to obtain an OctreoScan®, provided the patient returns to
             the Octreotide LAR fixed dose after the OctreoScan® has been obtained.

          6. Confirmed presence of somatostatin receptors on all target lesions (for
             target/non-target/measurable lesions definition see §Appendix 2, Section 1 and 2,
             RECIST Criteria, Version 1.1) documented by CT/MRI scans, based on positive
             OctreoScan® imaging within 24 weeks prior to randomization in the study (to be
             centrally confirmed). The OctreoScan® should be one that was performed while the
             patient was on a fixed dose of Octreotide LAR. If a patient has had an OctreoScan®
             performed while Octreotide LAR treatment-naïve, the patient must have a repeat
             OctreoScan® performed after 3 months of Octreotide LAR treatments before entering the
             clinical study to prove that the index lesions or new lesions still meet the criteria
             for inclusion. It is acceptable to have patients temporarily switched to Octreotide
             s.c. (up to six weeks) in order to obtain an OctreoScan®, provided they return to the
             same fixed dose of Octreotide LAR prior to the scan.

          7. The tumour uptake observed in each target lesion (for target/non-target/measurable
             lesions definition see §Appendix 2, Sections 1 and 2, RECIST Criteria, Version 1.1)
             using OctreoScan® must be ≥ normal liver uptake observed on planar imaging (to be
             centrally confirmed) (§Appendices 5 and 6).

          8. Karnofsky Performance Score (KPS)&gt;=60.

          9. Presence of at least 1 measurable site of disease.

         10. [Applicable only for France] All patients included in the trial must be affiliated
             with a social security regime or be a beneficiary of the same in order to be included
             in the study.

        Exclusion Criteria:

          1. Either serum creatinine &gt;150 µmol/L (&gt;1.7 mg/dL), or creatinine clearance &lt;50 mL/min
             calculated by the Cockroft Gault method, eventually confirmed by measured creatinine
             clearance (or measured glomerular filtration rate (GFR) using plasma clearance
             methods, not gamma camera-based) &lt;50 mL/min (the measured creatinine clearance / GFR
             is required only as confirmatory exam).

          2. Hb concentration &lt;5.0 mmol/L (&lt;8.0 g/dL); WBC &lt;2x109/L (2000/mm3); platelets &lt;75x109/L
             (75x103/mm3).

          3. Total bilirubin &gt;3 x ULN.

          4. Serum albumin &lt;3.0 g/dL unless prothrombin time is within the normal range.

          5. Pregnancy or lactation.

          6. For female patients of childbearing potential (defined as &lt; 2 years after last
             menstruation and not surgically sterile) and male patients, who are not surgically
             sterile or with female partners of childbearing potential: absence of effective,
             non-hormonal means of contraception (intrauterine contraceptive device, barrier method
             of contraception in conjunction with spermicidal gel) as defined in §Appendix 7.

          7. Treatment with &gt;30 mg Octreotide LAR at 3-4 weeks intervals within 12 weeks prior to
             randomization in the study.

          8. Peptide receptor radionuclide therapy (PRRT) at any time prior to randomization in the
             study.

          9. Any surgery, radioembolization, chemoembolization, chemotherapy and radiofrequency
             ablation within 12 weeks prior to randomization in the study.

         10. Interferons, Everolimus (mTOR-inhibitors) or other systemic therapies within 4 weeks
             prior to randomization in the study.

         11. Known brain metastases, unless these metastases have been treated and stabilized for
             at least 24 weeks, prior to enrollment in the study. Patients with a history of brain
             metastases must have a head CT with contrast to document stable disease prior to
             randomization in the study.

         12. Uncontrolled congestive heart failure (NYHA II, III, IV).

         13. Uncontrolled diabetes mellitus as defined by a fasting blood glucose &gt;2 ULN.

         14. Any patient receiving treatment with short-acting Octreotide, which cannot be
             interrupted for 24 h before and 24 h after the administration of
             177Lu-DOTA0-Tyr3-Octreotate, or any patient receiving treatment with Octreotide LAR,
             which cannot be interrupted for at least 6 weeks before the administration of
             177Lu-DOTA0-Tyr3-Octreotate, unless the tumour uptake on target lesions observed by
             OctreoScan® imaging during continued Octreotide LAR treatment is at least as high as
             normal liver uptake observed by planar imaging.

         15. Patients with any other significant medical, psychiatric, or surgical condition,
             currently uncontrolled by treatment, which may interfere with the completion of the
             study.

         16. Prior external beam radiation therapy to more than 25% of the bone marrow.

         17. Current spontaneous urinary incontinence.

         18. Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in
             situ of the uterine cervix, unless definitively treated and proven no evidence of
             recurrence for 5 years.

         19. Patients who have not provided a signed informed consent form to participate in the
             study, obtained prior to the start of any protocol related activities.

         20. Patient with known incompatibility to CT Scans with I.V. contrast due to allergic
             reaction or renal insufficiency. If such a patient can be imaged with MRI, then the
             patient would not be excluded.

         21. Patients who have participated in any therapeutic clinical study/received any
             investigational agent within the last 30 days are excluded from participation in this
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Santoro, Biologist</last_name>
    <role>Study Director</role>
    <affiliation>Advanced Accelerator Applications</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center Samuel Oschin Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Medical Faculty Foundation</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excel Diagnostics and Nuclear Oncology Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Oncology, Leuven Cancer Institute</name>
      <address>
        <city>Leuven</city>
        <state>Brabant Flamand</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <state>Ile De France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrénées</state>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu/CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <state>Pays De La Loire</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital la Timone /CHU Marseille</name>
      <address>
        <city>Marseille</city>
        <state>Provence-Alpes-Côte d'Azur</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Lyon</city>
        <state>Rhône-Alpes</state>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon AP-HP</name>
      <address>
        <city>Clichy Cedex</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Isar, Nuclear Medicine</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz, Medizinische Klinik I Schwerpunkt Endokrinologie</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <state>Thüringen</state>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Virchow-Klinikum, Gastroentrology, Hepatology &amp; Endocrinology</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Romagnolo per lo Studio dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>Emilia-Romagna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IEO Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Osp. Di Macerata</name>
      <address>
        <city>Macerata</city>
        <state>Marche</state>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Pisana (Presidio Ospedaliero S. Chiara)</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università &quot;Sapienza&quot; di Roma, Facoltà di Medicina e Psicologia, Ospedale S. Andrea-Roma</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitario de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <state>Centro</state>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia</name>
      <address>
        <city>Porto</city>
        <state>Norte</state>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat (Barcelona)</city>
        <state>Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramon y Cajal University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford</name>
      <address>
        <city>Oxford</city>
        <state>South East England</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Oncology Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare Trust, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <results_first_submitted>August 29, 2017</results_first_submitted>
  <results_first_submitted_qc>August 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2017</results_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuroendocrine tumour</keyword>
  <keyword>177Lu-Dota0-Tyr3-octreotate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall Study Table includes all subjects who were enrolled prior to the primary endpoint data cutoff when 74 events of progression free survival were reached (24 July 2015).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>177Lu-DOTA0-Tyr3-Octreotate</title>
          <description>Cumulative dose of 29.6 GBq (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate delivered over 4 doses
Dosing regimen:
4 doses of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered in 8±1-week intervals. Intervals could be extended up to 16 weeks to accommodate resolving acute toxicity (see Dose Modifying Toxicity (DMT) below)
amino acids will be given with each administration for kidney protection;
Patients experiencing clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, were given 30 mg Octreotide LAR s.c. rescue injections for symptom control purpose, unless the patient progresses or dies.</description>
        </group>
        <group group_id="P2">
          <title>Octreotide LAR</title>
          <description>60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the patient progresses or dies (see Dose Modifying Toxicity (DMT));
In case patients experience clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections are allowed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients who were randomized in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>177Lu-DOTA0-Tyr3-Octreotate</title>
          <description>Cumulative dose of 29.6 GBq (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate delivered over 4 doses
Dosing regimen:
4 doses of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered in 8±1-week intervals. Intervals could be extended up to 16 weeks to accommodate resolving acute toxicity (see Dose Modifying Toxicity (DMT) below)
amino acids will be given with each administration for kidney protection;
Patients experiencing clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, were given 30 mg Octreotide LAR s.c. rescue injections for symptom control purpose, unless the patient progresses or dies.</description>
        </group>
        <group group_id="B2">
          <title>Octreotide LAR</title>
          <description>60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the patient progresses or dies (see Dose Modifying Toxicity (DMT));
In case patients experience clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections are allowed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="116"/>
            <count group_id="B2" value="113"/>
            <count group_id="B3" value="229"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="9.4"/>
                    <measurement group_id="B2" value="64.1" spread="9.7"/>
                    <measurement group_id="B3" value="63.7" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
CT/MRI tumour assessment in both arms are performed every 12±1 weeks from the first treatment date.</description>
        <time_frame>after 74 centrally confirmed cases disease progression or death</time_frame>
        <population>Full analysis data set</population>
        <group_list>
          <group group_id="O1">
            <title>177Lu-DOTA0-Tyr3-Octreotate</title>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR</title>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
CT/MRI tumour assessment in both arms are performed every 12±1 weeks from the first treatment date.</description>
          <population>Full analysis data set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median progression free survival was not yet reached for 177Lu-DOTA0-Tyr3-Octreotate arm at the time the primary endpoint was evaluated (after 74 events of disease progression or death across study).</measurement>
                    <measurement group_id="O2" value="8.5" lower_limit="5.8" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessments (Adverse Events, Laboratory Parameters, Cancer Related Symptoms, Physical Examination, Vital Signs, Karnofsky Performance Status, ECG)</title>
        <description>The following parameters will be monitored:
Changes from Baseline in Hematology (WBC, platelets, haemoglobin, MCV), Blood chemistry (BUN, serum creatinine and creatinine clearance, uric acid, albumin, total bilirubin, AP, aspartate aminotransferase [AST/ASAT], alanine aminotransferase [ALT/ALAT], gamma-glutamyl transferase [γ-GT], [Na], [K], lactic dehydrogenase [LDH], glycosylated hemoglobin/hemoglobin A1c [glycoHb], free thyroxine [fT4]) and Urinalysis (RBC/hpf, WBC/hpf, casts/lpf, protein, 5-HIAA),
Cancer related symptoms,
Physical Examination, including heart rate, blood pressure and weight,
Karnofsky Performance Status,
ECG intervals.
All AEs and SAEs reported (spontaneously or not) by the patient will be collected during the study.</description>
        <time_frame>Data for this outcome measure are posted in the Adverse Events section below. Adverse Events table includes all treatment emergent adverse events collected from date of first enrollment (10 Jul 2012) to 30 June 2016.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Safety and Efficacy Assessment</title>
        <description>Any progressive patient ceases treatment/assessment and proceeds to long-term follow-up assessment.
Any non-progressive patients continues treatment/assessments until the PFS Primary End-Point, then:
Patients who have 76week or more treatment/assessment stop treatment but continue the long-term follow-up assessments for 5 years overall from the date of randomization of the last randomized.
Remaining randomized patients continue in the fixed 76-week treatment/assessment phase unless progression occurs, then proceed to the long-term follow-up assessment phase for 5 years overall from the date of randomization of the last randomized patient.
During the long-term follow-up assessment phase, toxicities suspected in relation with the study drug (including haematology, biochemistry, urine analyses), anti-tumour treatment administered after progression/discontinuation, disease status based on local CT/MRI assessment, and OS data will be collected every 6 months.</description>
        <time_frame>Every 6 months for a period of up to 5 years after the end of the study</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory Objectives</title>
        <description>To explore the correlation of toxicity outcomes and administered radioactivity corrected for body weight and body surface area;
To explore the correlation of clinical efficacy outcomes with the levels of the biomarkers Chromogranin-A (CgA) in the serum and 5-Hydroxyindoleacetic acid (5-HIAA) in the urine;
To evaluate dosimetry, pharmacokinetics (PK) and ECG in a subset of 20 patients;
To explore the correlation of clinical efficacy outcomes with OctreoScan® tumour uptake score;
To explore the correlation of clinical outcomes with serum levels of Alkaline Phosphatase (AP):
To evaluate the Duration of Response (DoR) in the two study arms;
To evaluate the Time to Second Progression (PFS2) in the two study arms</description>
        <time_frame>Study Treatment Phase</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event listing based on cutoff date of 30 June 2016, and includes data for 2 patients randomized after primary endpoint cutoff (74 events of PFS) was achieved.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>177Lu-DOTA0-Tyr3-Octreotate</title>
        </group>
        <group group_id="E2">
          <title>Octreotide LAR</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Refractory cytopenia with unilineage dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Haemotochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Malignant bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Complication of device insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Generalized edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Injection site hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Carcinoid crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Refractory cytopenia with multilineage dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Tumor invasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Inferior vena cava</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="112"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="18" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="16" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="161" subjects_affected="72" subjects_at_risk="112"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="125" subjects_affected="58" subjects_at_risk="112"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="41" subjects_affected="29" subjects_at_risk="112"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="40" subjects_affected="27" subjects_at_risk="112"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="112"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="112"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="61" subjects_affected="42" subjects_at_risk="112"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="25" subjects_affected="18" subjects_at_risk="112"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="24" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="35" subjects_affected="23" subjects_at_risk="112"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="112"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="112"/>
                <counts group_id="E2" events="28" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="112"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="112"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="112"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="112"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paola Santoro, Ph.D., Senior Clinical Study Manager</name_or_title>
      <organization>Advanced Accelerator Applications</organization>
      <phone>917-854-1313</phone>
      <email>paola.santoro@adacap.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

